For patients who are prescribed ELREXFIO, Pfizer offers the support of Patient Access Navigators, through our Pfizer Oncology Together program, who provide personalized services for all aspects of treatment, including financial assistance resources, treatment support, and resources to nav...
Pfizer Completes Acquisition of Seagen Reimagining the Future of Cancer Care, Together (LinkedIn) This a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology or...
Pfizer Oncology Together Co-Pay Savings Program (injectable products) Terms and Conditions By using this Co-Pay Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below: ...
“In addition, we completed the acquisition of Seagen inDecember 2023, a critical step toward our goal to achieve world-class Oncology leadership. With the combined strength of Pfizer’s and Seagen’s talent, portfolios and platforms, we believe we have the potential to transf...
Watson Health and Pfizer announce a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer. Expand to see more 2017 Pfizer and Corning Incorp...
Interest in Oncology helpful Aptitude for learning Reliable and able to meet deadlines. Extracurricular interests & achievements Good awareness of the UK healthcare environment and customer types (e.g. GPs, consultants, pharmacists, nurses etc.) Able to work well within a team and individual...
For example, oncology and urology share the longest Phase 1 transition at 2.7 years. Oncology is the only therapeutic area with an average regulatory review of less than 1 year; the 0.8-year duration is almost half as short as the cumulative total for all non-oncology indications (1.4 years...
Inflammation and Immunology Internal Medicine Oncology Rare Diseases Vaccines Therapeutic Modalities and Technology Platforms Medicine Design Biotherapeutics Discovery & Development Small Molecule Product & Process Development Biologics Product & Process Development ...
(ADC) technology with the scale and strength of Pfizer's capabilities and expertise. Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer's position in this important space and contribute meaningfully to the achievement of Pfizer's near- ...
We have also started to reshape the Group’s portfolio through prioritisation of R&D programmes, acquisitions such as that proposed with the oncology biopharmaceutical company, TESARO, the minority buy-out of the consumer healthcare business and a series of non-core ...